Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Companies

Set Alert for Companies

Calliditas IPO To Support Phase III Berger's Disease Study

Calliditas is aiming to raise new funding in an IPO and listing on Nasdaq Sweden to support late-stage clinical development and commercialization of its Berger's disease candidate, and studies in additional indications.

 

Financing Renal Research & Development
Advertisement

Companies

Latest From Companies

ViiV CEO: "We Aim To Be Top HIV Player By Mid-2020s"

ViiV CEO predicts strong pipeline and two-drug strategy will reinforces group's HIV market position and put it ahead of Gilead by the mid-2020s.

Analysis Business Strategies

Tech Transfer Roundup: Amgen Teams With MD Anderson To Accelerate Early-Stage Cancer Candidates

In a busy month, MD Anderson also partners with Ipsen on an unspecified cancer drug and licenses poziotinib IP to Spectrum. Using IP from UCLA, Bloom launches with focus on neuroprotective epilepsy therapies.

Deals Intellectual Property

£88m Series B For Syncona-backed Freeline To Advance Liver Gene Therapy Focus

Chairman says Freeline's series B financing gives it adequate funds for Phase I/II trials in hemophilia B and entry into Fabry disease.

Financing Blood & Coagulation Disorders

Interview: Novartis Counts On AS and PsA For Cosentyx Growth

Novartis immunology chief Eric Hughes tells Scrip a wealth of data is showing that early treatment with Cosentyx can prevent the structural changes that lead to lack of mobility in ankylosing spondylitis and psoriatic arthritis patients.

Immune Disorders Clinical Trials

ViiV Boosted By Early GEMINI Data, But More Details Wanted

ViiV Healthcare has positive early pivotal data for its second two-drug regimen for HIV, but more reassurance is needed on the relative rates of virologic suppression in patients with low and high viral loads, as well as on the long-term risk of virologic failure. The combination should help form ViiV's defense against rival Gilead and its new triple combination Biktarvy.

Clinical Trials Companies

Galmed To Design Phase III NASH Trial With FDA After Strong Aramchol Data

The Israel-based biopharma company said a Phase IIb trial of its oral treatment of non-alcoholic steatohepatitis hit the necessary endpoints to support a Phase III trial and FDA marketing application.

Clinical Trials Companies
See All
UsernamePublicRestriction

Register